Status:
COMPLETED
Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborating Sponsors:
Quebec Firefighters Foundation for Burns
Conditions:
Delirium
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Background: Delirium is an important problem in critical care. Its prevalence often reaches 75% in intensive care patients. Its occurrence is associated with numerous complications and deleterious co...
Detailed Description
Primary Outcome Measures: •Time to first resolution of delirium. Secondary Outcome Measures: * Days in delirium during the study * Duration of delirium * Severity of delirium (highest Nu-DESC score...
Eligibility Criteria
Inclusion
- Patients aged 18 years or older.
- Patients with a diagnosis of delirium made by a psychiatrist.
Exclusion
- Patients with active schizophrenia or bipolar disorder.
- Patients with Parkinson disease.
- Patients with severe liver failure.
- Patients with alcohol or sedative/hypnotics dependence.
- Patients with QTc interval above 500 msec.
- Pregnant patients.
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT01811459
Start Date
February 1 2013
End Date
September 1 2016
Last Update
February 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada, H2W 1T8